Matthew J. Ellis

Guardant (United States)

Full Professor(heuristic)

Advanced Breast Cancer Therapies · Pulmonary and Respiratory Medicine

h-index110

i10-index327

Publications1,080

Citations67,761

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 103

Table S6 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Table S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Table S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S18 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S12 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S17 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S19 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S3 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Table S2 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S13 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S15 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S10 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S9 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S7 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Table S4 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S16 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S8 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17
Figure S4 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
2026-06-17

Open author page on OpenAlex →